Risk Factors for Major Adverse Cardiovascular Events, Malignancies, and Serious Infections With Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of a 3‐Year J‐Post‐Marketing Surveillance
Older age was a risk factor for all AEs (MACE, malignancies, and SI). MACE risk was also increased in patients with ≥ 1 CV risk factors versus those without. SI risk might also be increased in patients with ≥ 1 CV risk factors.
Authors
- Kunihiro Yamaoka (ORCID: https://orcid.org/0000-0001-8858-9435)
- Toshitaka Hirano
- Yutaka Endo (ORCID: https://orcid.org/0000-0002-7985-8880)
- Masato Hoshi (ORCID: https://orcid.org/0000-0003-2874-1807)
Institutions
- Pfizer (Japan) (JP)
- Kitasato University (JP)
Publication Details
- Journal
- International Journal of Rheumatic Diseases
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1111/1756-185x.70572
- Citations
- 1
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 46.80
Funders
- Pfizer